Form 4: Centessa CAO Granted Equity Awards

Centessa Pharmaceuticals' Chief Accounting Officer, Raphael Deferiere, was granted 11,000 Restricted Share Units and options for 42,000 Ordinary Shares.

Summary

• Raphael Deferiere, Chief Accounting Officer of Centessa Pharmaceuticals plc, received equity awards on February 2, 2026.
• The awards include 11,000 Restricted Share Units (RSUs) and options to purchase 42,000 Ordinary Shares.
• The RSUs will vest in four equal annual installments, with the first vesting on February 2, 2027.
• The share options have an exercise price of $25.19 and will vest in 48 equal monthly installments, with the first vesting on March 2, 2026.
• The share options have an expiration date of February 2, 2036.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development for corporate governance and executive alignment, as it ties a key officer's compensation directly to the company's long-term performance, though it is a routine transaction.

Positives

• The grant of equity awards to the Chief Accounting Officer aligns management's interests with those of shareholders.
• The multi-year vesting schedules for both RSUs and share options incentivize long-term performance and executive retention.

Future Outlook

The equity grants, with their multi-year vesting schedules, indicate a long-term commitment to the company's future performance and executive retention, aligning the Chief Accounting Officer's incentives with the company's strategic goals.

Industry Context

StockSavvy.ai notes that equity grants to key executives are a standard practice across the biotechnology and pharmaceutical industries. This strategy is commonly employed to align leadership incentives with long-term shareholder value creation and to retain critical talent in a highly competitive market.

Comparison to Industry Standards

• Equity grants of this nature, combining Restricted Share Units and stock options with multi-year vesting, are consistent with compensation practices observed at comparable biotechnology firms.
• For instance, companies like Moderna or BioNTech frequently utilize similar long-term incentive structures for their executive teams to foster innovation and sustained growth, ensuring executive compensation is tied to company performance over several years.

Stakeholder Impact

• Shareholders: Potential long-term benefit from enhanced executive retention and performance alignment.
• Employees: May signal stability and commitment from leadership, potentially boosting morale.

Next Steps

• Vesting of 1/48th of the share options monthly, commencing March 2, 2026.
• Vesting of 1/4th of the Restricted Share Units annually, commencing February 2, 2027.

Key Dates

Recommendation

This Form 4 reports a routine equity grant to a key executive, which is a positive for aligning management incentives with shareholder interests. However, it does not provide new fundamental information to warrant a change in investment recommendation. Investors should continue to hold based on broader company performance and market conditions.

Keywords

Centessa Pharmaceuticals, CNTA, Form 4, Insider Transaction, Equity Grant, Restricted Share Units, Stock Options, Executive Compensation, Raphael Deferiere